VanEck Biotech ETF
BBH
71 hedge funds and large institutions have $120M invested in VanEck Biotech ETF in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 30 reducing their positions, and 25 closing their positions.
64% more call options, than puts
Call options by funds: $6.29M | Put options by funds: $3.83M
1.88% less ownership
Funds ownership: 24.14% → 22.25% (-1.9%)
21% less funds holding
Funds holding: 90 → 71 (-19)
28% less capital invested
Capital invested by funds: $167M → $120M (-$47.4M)
43% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 30
68% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.42M |
| 2 |
VF
Virtu Financial
New York
|
+$2.81M |
| 3 |
AL
Aspiriant LLC
Los Angeles,
California
|
+$2.66M |
| 4 |
SG Americas Securities
New York
|
+$2.25M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$980K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.85M |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$2.19M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.69M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.44M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$1.39M |
BBH Hedge Fund Activity: Q1 2016 in Review
71 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2016, worth a combined $120M — down 28% from $167M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of BBH and 8 opened new positions — a net loss of 17 holders — while 30 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $4.42M. The largest seller was Credit Suisse, exiting entirely with an estimated $8.85M sold.
- 71 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2016, down from 90 in Q4 2015.
- Funds reported $120M of VanEck Biotech ETF stock for Q1 2016, down 28% quarter-over-quarter.
- 8 funds opened new VanEck Biotech ETF positions in Q1 2016 and 25 closed out, a net change of -17 holders.
- The largest VanEck Biotech ETF buyer in Q1 2016 was Morgan Stanley, an estimated $4.42M added.
- The largest VanEck Biotech ETF seller in Q1 2016 was Credit Suisse, an estimated $8.85M sold.
Based on aggregated 13F filings for Q1 2016.